Supplementary protection
LT - (R)-1(2,2-difluorbenzo(d)(1,3)dioksol-5-il)-N-(1-(2,3-dihidroksipropil)-6-fluor-2-(1-hidroksi-2-metilpropan-2-il)-1H-indol-5-il)-ciklopropankarboksamido kieta amorfinės formos dispersija
EN - SOLID DISPERSION OF AMORPHOUS FORM OF (R)-1(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)-CYCLOPROPANECARBOXAMIDE
SPC
| (11) |
Number of the document |
C 2826776 |
| (68) |
Number of the document |
2826776
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2021 508 |
| (22) |
Date of filing the application |
2021-05-14 |
| (41) |
Date of publication of the application |
2021-06-10 |
|
Date of publication of SPC |
2023-12-11 |
| (24) |
Date of coming into effect of SPC |
2031-03-26 |
Applicant
| (71) |
Vertex Pharmaceuticals Incorporated,
50 Northern Avenue, Boston, MA 02210,
US
|
Grantee
| (73) |
Vertex Pharmaceuticals Incorporated,
50 Northern Avenue, Boston, MA 02210,
US
|
Attorney or representative
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/18/1306, 2018-10-31
|
Calculated date of expiry of the SPC
| (94) |
2033-11-06 |
Name of the product protected by the basic patent
| (95) |
(a) (R)-1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)-N-(1-(2,3-dihidroksipropil)-6-fluor-2-(1-hidroksi-2-metilpropan-2-il)-1H-indol-5-il) ciklopropankarboksamido arba farmaciškai priimtinos jo druskos ir (b) N-(5-hidroksi-2,4-ditert-butil-fenil)-4-okso-1H-chinolin-3-karboksamido arba farmaciškai priimtinos jo druskos derinys |
